Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
Unlike other psychodermatological disorders, the patient often readily accepts the skin-picking behavior
GLP-1 receptor agonists with indication for obesity As mentioned earlier, there are 2 GLT-1 receptor agonists indicated for the treatment of obesity in the EU in subjects with BMI 30kg/m2 or BMI 27kg/m2 and at least one weight-related comorbidity, always in combination with appropriate diet and physical exercise: liraglutide 3mg and semaglutide 2.4 mg
Your primary care physician, a gastroenterologist, and a general surgeon form a powerful team dedicated to your digestive health and overall well-being
